CL2022002136A1 - Moduladores de la monoacilglicerol lipasa. - Google Patents
Moduladores de la monoacilglicerol lipasa.Info
- Publication number
- CL2022002136A1 CL2022002136A1 CL2022002136A CL2022002136A CL2022002136A1 CL 2022002136 A1 CL2022002136 A1 CL 2022002136A1 CL 2022002136 A CL2022002136 A CL 2022002136A CL 2022002136 A CL2022002136 A CL 2022002136A CL 2022002136 A1 CL2022002136 A1 CL 2022002136A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- disorders
- modulators
- monoacylglycerol lipase
- depression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de azabiciclo 3.1.0 y 4.1.0 de la Fórmula (I), composiciones farmacéuticas que los contienen, métodos para elaborarlos, y métodos para usarlos que incluyen métodos para tratar estados de enfermedad, trastornos, y afecciones asociados con la modulación de la MGL, tales como aquellos asociados con el dolor, los trastornos psiquiátricos, los trastornos neurológicos (incluidos, pero que no se limitan a, el trastorno depresivo mayor, la depresión resistente al tratamiento, la depresión ansiosa, el trastorno bipolar), los cánceres y las afecciones oculares. ; en donde X, Y, R1 , R2a y R2b se definen en la presente descripción
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062972484P | 2020-02-10 | 2020-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022002136A1 true CL2022002136A1 (es) | 2023-02-03 |
Family
ID=74595268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022002136A CL2022002136A1 (es) | 2020-02-10 | 2022-08-08 | Moduladores de la monoacilglicerol lipasa. |
Country Status (21)
Country | Link |
---|---|
US (2) | US11708359B2 (es) |
EP (1) | EP4103557A1 (es) |
JP (1) | JP2023512729A (es) |
KR (1) | KR20220140581A (es) |
CN (1) | CN115066422A (es) |
AR (1) | AR121296A1 (es) |
AU (1) | AU2021220539A1 (es) |
BR (1) | BR112022015116A2 (es) |
CA (1) | CA3169988A1 (es) |
CL (1) | CL2022002136A1 (es) |
CO (1) | CO2022011275A2 (es) |
CR (1) | CR20220376A (es) |
DO (1) | DOP2022000162A (es) |
EC (1) | ECSP22062460A (es) |
IL (1) | IL295447A (es) |
JO (1) | JOP20220180A1 (es) |
MX (1) | MX2022009804A (es) |
PE (1) | PE20221576A1 (es) |
TW (1) | TW202140465A (es) |
UY (1) | UY39066A (es) |
WO (1) | WO2021160602A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3169988A1 (en) | 2020-02-10 | 2021-08-19 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
WO2021191390A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Azaspirocycles as monoacylglycerol lipase modulators |
CA3176113A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
CN115362151A (zh) | 2020-03-26 | 2022-11-18 | 詹森药业有限公司 | 作为单酰基甘油脂肪酶调节剂的芳基哌啶 |
AU2022328310A1 (en) | 2021-08-09 | 2024-03-28 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators for use in autism spectrum disorders |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2493637A1 (en) | 2002-07-25 | 2004-02-12 | Manuela Villa | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
EP2760450A1 (en) * | 2011-09-30 | 2014-08-06 | Janssen Pharmaceutica, N.V. | Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders |
EP3438109B1 (en) | 2016-03-31 | 2021-08-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
AR108012A1 (es) | 2016-03-31 | 2018-07-04 | Takeda Pharmaceuticals Co | Derivados de azaespiro[3,4]octan-6-ona como inhibidores de magl |
CN111148746B (zh) * | 2017-09-29 | 2022-08-05 | 武田药品工业株式会社 | 杂环化合物 |
WO2020211798A1 (zh) | 2019-04-16 | 2020-10-22 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
CA3169988A1 (en) | 2020-02-10 | 2021-08-19 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
WO2021191390A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Azaspirocycles as monoacylglycerol lipase modulators |
CA3176113A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
CN115362151A (zh) | 2020-03-26 | 2022-11-18 | 詹森药业有限公司 | 作为单酰基甘油脂肪酶调节剂的芳基哌啶 |
-
2021
- 2021-02-09 CA CA3169988A patent/CA3169988A1/en active Pending
- 2021-02-09 KR KR1020227031216A patent/KR20220140581A/ko unknown
- 2021-02-09 JO JOP/2022/0180A patent/JOP20220180A1/ar unknown
- 2021-02-09 CN CN202180013762.3A patent/CN115066422A/zh active Pending
- 2021-02-09 US US17/171,559 patent/US11708359B2/en active Active
- 2021-02-09 WO PCT/EP2021/053062 patent/WO2021160602A1/en active Application Filing
- 2021-02-09 BR BR112022015116A patent/BR112022015116A2/pt unknown
- 2021-02-09 AU AU2021220539A patent/AU2021220539A1/en active Pending
- 2021-02-09 AR ARP210100333A patent/AR121296A1/es unknown
- 2021-02-09 UY UY0001039066A patent/UY39066A/es unknown
- 2021-02-09 IL IL295447A patent/IL295447A/en unknown
- 2021-02-09 TW TW110104960A patent/TW202140465A/zh unknown
- 2021-02-09 JP JP2022548400A patent/JP2023512729A/ja active Pending
- 2021-02-09 MX MX2022009804A patent/MX2022009804A/es unknown
- 2021-02-09 PE PE2022001698A patent/PE20221576A1/es unknown
- 2021-02-09 CR CR20220376A patent/CR20220376A/es unknown
- 2021-02-09 EP EP21705124.2A patent/EP4103557A1/en active Pending
-
2022
- 2022-08-08 CL CL2022002136A patent/CL2022002136A1/es unknown
- 2022-08-09 EC ECSENADI202262460A patent/ECSP22062460A/es unknown
- 2022-08-10 CO CONC2022/0011275A patent/CO2022011275A2/es unknown
- 2022-08-10 DO DO2022000162A patent/DOP2022000162A/es unknown
-
2023
- 2023-06-02 US US18/328,242 patent/US20230382902A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210253565A1 (en) | 2021-08-19 |
JP2023512729A (ja) | 2023-03-28 |
AR121296A1 (es) | 2022-05-04 |
BR112022015116A2 (pt) | 2022-09-27 |
DOP2022000162A (es) | 2022-10-31 |
JOP20220180A1 (ar) | 2023-01-30 |
TW202140465A (zh) | 2021-11-01 |
UY39066A (es) | 2021-08-31 |
AU2021220539A1 (en) | 2022-10-06 |
PE20221576A1 (es) | 2022-10-06 |
US11708359B2 (en) | 2023-07-25 |
US20230382902A1 (en) | 2023-11-30 |
MX2022009804A (es) | 2022-09-02 |
IL295447A (en) | 2022-10-01 |
CO2022011275A2 (es) | 2022-08-30 |
CR20220376A (es) | 2022-09-16 |
EP4103557A1 (en) | 2022-12-21 |
ECSP22062460A (es) | 2022-11-30 |
CN115066422A (zh) | 2022-09-16 |
KR20220140581A (ko) | 2022-10-18 |
WO2021160602A1 (en) | 2021-08-19 |
CA3169988A1 (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022002136A1 (es) | Moduladores de la monoacilglicerol lipasa. | |
NI202100023A (es) | Moduladores de monoacilglicerol lipasa | |
Géléoc et al. | Sound strategies for hearing restoration | |
MX2022011904A (es) | Aminociclobutanos como moduladores de monoacilglicerol lipasa. | |
MX2022011903A (es) | Azaspirociclos como moduladores de monoacilglicerol lipasa. | |
BR112022019155A2 (pt) | Aril piperidinas como moduladores da monoacilglicerol lipase | |
BR112022019077A2 (pt) | Moduladores da monoacilglicerol lipase | |
PE20090729A1 (es) | Moduladores de gamma-secretasa | |
Adatia et al. | Proprioceptive innervation of the tongue. | |
AR038483A1 (es) | Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides | |
CL2023001195A1 (es) | Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades. | |
PE20212196A1 (es) | Compuestos, composiciones, y metodos para modular la actividad cdk9 | |
EA201992127A1 (ru) | ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ АЛИЦИКЛИЧЕСКИ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА | |
UY38304A (es) | Dinucleótidos cíclicos como agonistas de sting y composiciones farmacéuticas que los contienen | |
PE20230106A1 (es) | Compuestos de pirimidina fusionados como moduladores de kcc2 | |
MX2023003240A (es) | Moduladores de monoacilglicerol lipasa de ciclobutilamida. | |
CO6280529A2 (es) | DERIVADOS DE AMIDA AROMÁTICOS DE ÁCIDO PENTANOICO COMO MODULADORES DE γ - SECRETOSA | |
DOP2022000127A (es) | Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos. | |
El-Hashash | Neural crest stem cells: a therapeutic hope machine for neural regeneration | |
CO2023003078A2 (es) | Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de células falciforme | |
AR127356A1 (es) | Moduladores de micromoléculas de la actividad de la glucocerebrosidasa y usos de estos | |
CO2024002084A2 (es) | Compuestos n-acilidrazónicos inhibidores de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de estos y kits | |
AR124316A1 (es) | Compuestos para tratar una enfermedad respiratoria | |
Марянян et al. | Cell technologies in regenerative medicine | |
Lopes et al. | Stem Cell Applications for Neurodegenerative Diseases |